

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Bio-heart Biological Technology Co., Ltd.

上海百心安生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2185)

**COMPLETION OF REPURCHASE AND CANCELLATION OF H SHARES
IN RELATION TO THE 2022 H SHARE INCENTIVE SCHEME
AND THE REDUCTION OF REGISTERED SHARE CAPITAL**

Reference is made to the announcements of the Company dated May 23, 2025, June 2, 2025 and June 19, 2025 and the circular of the Company dated May 28, 2025 (the “**Circular**”) in relation to, among other things, the proposal for the repurchase and cancellation of H shares in relation to the 2022 H Share Incentive Scheme (the “**Proposal**”). Capitalized terms used herein shall have the same meanings as those defined in the Circular unless the context requires otherwise.

On June 19, 2025, the Proposal was considered and approved by way of a special resolution of the Shareholders at the AGM. On August 7, 2025, the Acquired Award Shares were acquired by the Company from the Trustee at nil consideration, and subsequently cancelled by the Company's H Share Registrar on the same date.

EFFECT ON THE SHAREHOLDING STRUCTURE OF THE COMPANY

The total number of the Acquired Award Shares being repurchased and cancelled represents approximately 0.21% of the total issued share capital of the Company prior to the completion of the repurchase and cancellation of the Acquired Award Shares. The following table illustrates the Company's shareholding structure (i) immediately before the completion of the repurchase and cancellation of the Acquired Award Shares; and (ii) immediately after the completion of the repurchase and cancellation of the Acquired Award Shares.

	Immediately before the completion of the repurchase and cancellation of Acquired Award Shares	Changes	Immediately after the completion of the repurchase and cancellation of the Acquired Award Shares
Number of H Shares	236,223,322	-519,900	235,703,422
Number of Unlisted Foreign Shares	<u>7,713,678</u>	<u>0</u>	<u>7,713,678</u>
Total number of Shares	<u><u>243,937,000</u></u>	<u><u>-519,900</u></u>	<u><u>243,417,100</u></u>

The registered share capital of the Company was also changed from RMB243,937,000 to RMB243,417,100 immediately after the completion of the repurchase and cancellation of the Acquired Award Shares.

The completion of the repurchase and cancellation of the Acquired Award Shares did not affect the public float of the Company as required under the Listing Rules.

By Order of the Board
Shanghai Bio-heart Biological Technology Co., Ltd.
Philip Li WANG
Chairman and executive director

Shanghai, the PRC, August 7, 2025

As at the date of this announcement, the Board comprises Mr. Philip Li WANG as Chairman and executive director, Mr. Yunqing WANG and Ms. Peili WANG as executive directors, and Mr. Yiqing CHEN, Mr. Xubo LU and Mr. Yifei JIANG as independent non-executive directors.